HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kauffman, C. A. Search for Related Content PubMed PubMed Citation Articles by Kauffman, C. A.

Fungal Infections

University of Michigan Medical School; and Infectious Diseases Section, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan

Correspondence and requests for reprints should be addressed to Carol A. Kauffman, M.D., Veterans Affairs Ann Arbor Healthcare System, 2215 Fuller Road, Ann Arbor, MI 48105. E-mail: ckauff{at}umich.edu

ABSTRACT

Over the last decade, there have been changes in the epidemiology of fungal infections as well as dramatic improvements in the antifungal armamentarium. Candida species are an increasingly important cause of infection among patients in intensive care units. Mold infections continue to occur predominantly among highly immunosuppressed patients, such as those who have acute leukemia and those undergoing hematopoietic stem cell or solid organ transplantation. Aspergillus species remain the most common molds to cause invasive infection, but other environmental molds, such as Scedosporium, Fusarium, and various zygomycetes, including Rhizopus and Mucor, appear to be increasing in some medical centers. We now have available a new class of antifungal agents, the echinocandins, that act to damage the cell walls of Candida and Aspergillus species. Although limited in spectrum and only available in intravenous formulations, these agents are very safe and extremely well tolerated. Another new agent is the expanded spectrum triazole voriconazole. This agent has a very broad spectrum of activity, is available in both oral and intravenous formulations, and is approved for treatment of aspergillosis, other molds, and candidiasis. The major drawbacks with voriconazole are the number of drug–drug interactions and side effects, including rash, hepatitis, and visual disturbances. Treatment with amphotericin B, long the mainstay of antifungal therapy despite its inherent toxicity, is required much less often since the introduction of these new antifungal agents.

Key Words: asperigillosis • candidiasis • echinocandins • triazoles • zygomycosis

This article has been cited by other articles:

				R. Bhabhra, D. L. Richie, H. S. Kim, W. C. Nierman, J. Fortwendel, J. P. Aris, J. C. Rhodes, and D. S. Askew Impaired Ribosome Biogenesis Disrupts the Integration between Morphogenesis and Nuclear Duplication during the Germination of Aspergillus fumigatus Eukaryot. Cell, April 1, 2008; 7(4): 575 - 583. [Abstract] [Full Text] [PDF]

				C. T. Norice, F. J. Smith Jr., N. Solis, S. G. Filler, and A. P. Mitchell Requirement for Candida albicans Sun41 in Biofilm Formation and Virulence Eukaryot. Cell, November 1, 2007; 6(11): 2046 - 2055. [Abstract] [Full Text] [PDF]

				M. G. Wise, M. Healy, K. Reece, R. Smith, D. Walton, W. Dutch, A. Renwick, J. Huong, S. Young, J. Tarrand, et al. Species identification and strain differentiation of clinical Candida isolates using the DiversiLab system of automated repetitive sequence-based PCR J. Med. Microbiol., June 1, 2007; 56(6): 778 - 787. [Abstract] [Full Text] [PDF]

				N. Isham and M. A. Ghannoum Determination of MICs of Aminocandin for Candida spp. and Filamentous Fungi J. Clin. Microbiol., December 1, 2006; 44(12): 4342 - 4344. [Abstract] [Full Text] [PDF]